Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Stocks Hitting 52-Week Highs

Benzinga.com  October 6, 2016

Mid-Morning Market Update: Markets Open Lower; Yum! Brands Sales Miss Estimates

Benzinga.com  October 6, 2016

Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis

Business Wire October 6, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 3, 2016

Mid-Day Market Update: Dow Surges Over 150 Points; Threshold Pharmaceuticals Shares Slide

Benzinga.com  September 30, 2016

Mid-Morning Market Update: Markets Open Higher; McCormick Profit Tops Estimates

Benzinga.com  September 30, 2016

16 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  September 30, 2016

IIROC Trade Resumption - AUP

Canada NewsWire September 30, 2016

IIROC Trade Resumption - Aurinia Pharmaceuticals Inc.

Newsfile September 30, 2016

Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN)

Business Wire September 29, 2016

IIROC Trading Halt - AUP (all issues)

Canada NewsWire September 29, 2016

IIROC Trade Halt - Aurinia Pharmaceuticals Inc.

Newsfile September 29, 2016

TechStockInsider.com: The Week Many Have Been Waiting For

PR Newswire September 26, 2016

Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016

Business Wire September 22, 2016

Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York

Business Wire September 21, 2016

Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference

Business Wire September 7, 2016

Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York

Business Wire July 28, 2016

Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)

Business Wire June 28, 2016

Aurinia Announces Closing of US$7 Million Private Placement

Business Wire June 22, 2016